United Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
The virtual annual meeting marked the company's 30th anniversary, with all director nominees elected and all shareholder proposals approved. No questions were raised by shareholders, and voting results will be reported in a forthcoming SEC filing.
-
Multiple late-stage clinical successes in IPF and PAH are driving confidence in achieving a $1 billion quarterly run rate by 2027, with further revenue growth expected from new indications and product launches. Expansion of the sales force and ongoing pivotal trials in PPF and xenotransplantation support a robust long-term outlook.
-
Significant clinical progress in IPF and PAH is expected to drive revenue growth, with TYVASO and ralinepag positioned for major label expansions. Regulatory filings and new product launches are on track, while organ manufacturing programs advance toward addressing unmet needs.
-
Q1 2026 revenue reached $782M, with TYVASO and Ralinepag phase III trials showing best-in-class results. Both drugs are expected to drive revenue beyond $4B by 2027, with multiple new formulations and indications in development.
-
Recent clinical trial successes position Tyvaso and ralinepag as leading therapies for pulmonary diseases, with rapid commercialization and significant revenue growth expected. The pipeline features innovative inhalers and organ manufacturing advances, while AI-driven models are streamlining drug development.
-
Strong clinical data for Ralinepag and Tyvaso support robust growth, with new launches and device innovations expected to drive significant market expansion. Xenotransplantation and pipeline programs offer major future opportunities, while capital allocation remains disciplined.
-
The Phase III ADVANCE OUTCOMES trial showed ralinepag significantly reduced clinical worsening in PAH patients, with a 55% risk reduction and consistent benefits across all subgroups. The once-daily oral therapy demonstrated strong tolerability and is expected to become a preferred frontline or add-on treatment.
-
IPF and super-prostacyclin are set to drive major growth, with Tyvaso showing game-changing results in IPF and ralinepag poised to lead in pulmonary hypertension. Expansion into orphan oncology and xenotransplantation further strengthens the pipeline.
Fiscal Year 2025
-
Record 2025 revenue surpassed $3B, driven by Tyvaso and Orenitram, with double-digit growth expected to continue. Three transformative product launches are planned by 2027, and a $4B run rate is targeted, excluding new launches.
-
Tyvaso and Tyvaso DPI drive robust growth, with resilience against new competitors and a $1B quarterly revenue run rate targeted by 2027. Strong IPF data and a broad pipeline, including organ transplantation, support long-term expansion.
-
Strong double-digit growth in Tyvaso, best-in-class IPF trial results, and pipeline progress underpin confidence in reaching a $4B revenue run rate by 2027. Xenotransplantation program achieved a first-in-human milestone, with further updates expected after initial cohort completion.
-
Record quarterly revenues of $800 million, up 7% year-over-year, driven by Tyvaso and Orenitram. Strong clinical progress in IPF and new product launches support a $4 billion revenue run rate by 2027, with continued growth expected in key segments.
-
The phase 3 TETON 2 study in IPF met its primary endpoint, showing a significant improvement in FVC with nebulized Tyvaso versus placebo, along with benefits in key secondary endpoints and a favorable safety profile. Consistent efficacy was observed across subgroups, supporting use as monotherapy or in combination.
-
The event highlighted robust growth, a strong pipeline, and innovative strategies in pulmonary and transplant medicine. Key milestones include best-in-class phase III results in pulmonary fibrosis, a transformative IPF launch, and pioneering xenotransplantation trials, with major regulatory filings and product launches expected by 2027.
-
TETON-2 clinical trial results for nebulized TYVASO in IPF were highly positive, supporting regulatory and commercial expansion plans. A $1B share repurchase was launched, and the xenotransplant program is advancing with new facilities and a large potential market.
-
Record Q2 revenue of $799M (up 12% YoY) driven by Tyvaso DPI and strong commercial portfolio. Pipeline advances include TETON-2 IPF data expected in September and a $1B share repurchase authorized, reflecting confidence in future growth.
-
Record Q1 revenue of $794M, up 17% year-over-year, driven by strong treprostinil product demand and robust pipeline progress. Double-digit growth is expected to continue, supported by strategic capital allocation and expansion into new indications.
-
Capital allocation remains focused on R&D, facility expansion, and shareholder returns, while Tyvaso DPI drives strong commercial growth with robust manufacturing capacity. Key clinical milestones include TETON and ADVANCE OUTCOMES trials, and the xenokidney program is set for its first transplant in 2024.
-
Strong commercial execution continues with Tyvaso and pipeline progress in IPF and PAH. Key clinical readouts are expected in 2024–2025, while payer contracting and product enhancements position the portfolio for growth amid new competition. Xenotransplantation capacity is expanding, with significant long-term revenue potential.
-
The conference highlighted robust financial growth, a multi-phase innovation strategy, and major clinical milestones in organ manufacturing and rare disease therapeutics. Facility expansion and disciplined capital allocation support ambitious revenue targets and ongoing shareholder returns.
Fiscal Year 2024
-
Record revenue growth of nearly 24% year-over-year was driven by strong performance across all major products and strategic investments in manufacturing and R&D. Continued double-digit growth is expected, with new clinical milestones and product launches anticipated in 2025.
-
Achieved a $3B revenue run rate with double-digit growth expected, driven by Tyvaso and portfolio expansion. Manufacturing and sales force capacity have scaled, with major clinical milestones in IPF and xenotransplantation targeted for 2025–2026.
-
Record Q3 revenue of $749M (up 23% YoY) driven by strong growth in Tyvaso, Orenitram, and Unituxin, with robust commercial execution and pipeline progress. Completed $1B share repurchase, maintained double-digit growth outlook, and advanced key clinical and regulatory milestones.
-
Strong commercial growth continues, led by PH-ILD and TYVASO, with expanding market penetration and investments in sales and education. Product differentiation and established relationships provide defenses against competition and generics. Pipeline advances in IPF and xenotransplantation offer significant future opportunities.
-
Capital allocation remains focused on business investment, BD, and share repurchases, with recent progress in all areas. Tyvaso DPI and PH-ILD markets show strong growth, supported by sales force expansion and new patient support initiatives. Pipeline advances in IPF and organ manufacturing offer significant future opportunities.
-
Record Q2 revenue of $715M marked 20% growth year-over-year, led by Tyvaso, Orenitram, Remodulin, and Unituxin. Strong commercial execution, ongoing clinical trials, and a robust capital allocation strategy support continued growth and innovation.
-
Leadership emphasized innovation in organ manufacturing and inhaled therapies, with Tyvaso DPI gaining market share and manufacturing capacity expanding. Organ assist and xenotransplantation programs are advancing toward clinical milestones, while capital allocation remains focused on growth and patient impact.